
|Videos|September 9, 2021
Examining new biological treatments in posterior uveitis
Author(s)Sheryl Stevenson, OT Staff Reports
Quan Dong Nguyen, MD, MSc, FARVO, FASRS, highlights his presentation regarding new biological treatments of posterior uveitis.
Advertisement
Quan Dong Nguyen, MD, MSc, FARVO, FASRS, director of the Uveitis and Ocular Inflammation Service, Byers Eye Institute, Stanford University School of Medicine, speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix randomizes first patient in HELIOS-3
2
AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care
3
Orasis Pharmaceuticals introduces starter packs of pilocarpine hydrochloride ophthalmic solution 0.4%
4
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
5


















































.png)


